A small acute mechanistic crossover study testing whether exenatide-glucagon co-infusion raises myocardial glucose uptake and a diastolic strain-rate marker in eight adults with type 2 diabetes. PICO summary and expert commentary.
Browsing: GLP-1 Receptor Agonists
A secondary analysis of the COORDINATE-Diabetes trial found that up to one-third of patients with Type 2 diabetes and atherosclerotic cardiovascular disease stopped their SGLT-2i or GLP-1RA within 12 months, with cost and side effects among the cited reasons. PICO summary and expert commentary.
A post hoc analysis of the ADJUNCT ONE and ADJUNCT TWO trials identifies who discontinues adjunctive liraglutide in type 1 diabetes: longer disease duration, undetectable C-peptide, and lower BMI. PICO summary and expert commentary.
An early-phase trial of the GLP-1/FGF21 dual agonist HEC88473 reported dose-proportional liver fat reduction and improved glycaemic control over 5 weeks in patients with MASLD and type 2 diabetes. PICO summary and expert commentary.
A 16-week randomized trial found combined training lowered GLP-1 and amylin and raised DPP-4 in adults with type 2 diabetes and overweight, without a demonstrated glycaemic benefit. PICO summary and expert commentary.
A phase 1, double-blind, placebo-controlled study of titrated noiiglutide (SHR20004) in obese Chinese adults without diabetes reported good tolerability and dose-related weight loss, with PICO summary and expert commentary.
A first-in-human phase 1 trial of oral amycretin in overweight or obesity found it safe and tolerable, with dose-dependent gastrointestinal effects and exploratory weight loss. PICO summary and expert commentary.
A phase 1 first-in-human study of the oral GLP-1 receptor agonist ECC5004/AZD5004 in healthy volunteers and T2DM patients found it well tolerated with early dose-dependent glucose and weight signals. PICO summary and expert commentary.
Summary: In adults with obesity, exposure to GLP-1 receptor agonists and bariatric surgery significantly increased policy support for obesity treatments…
An oral GLP-1 receptor agonist lowered HbA1c and body weight in phase 2 but was halted early after transaminase elevations ended its development. PICO summary and expert commentary.